Innovating Sustained-Release Technology for Effective Osteoarthritis Pain Management
Calosyn works with Lonza Biologics to Ensure Precision Manufacturing and Long-Lasting Drug Delivery.
Revolutionizing Drug Delivery with Sustained-Release Microspheres
At Calosyn, we understand that effective treatment goes beyond just the formulation of a drug—it’s about how that drug is delivered to ensure optimal results for patients.
Our research has led to the creation of sustained-release microspheres that encapsulate verapamil, a commonly used calcium channel blocker, allowing for consistent and controlled release directly into the joint. The microspheres are designed to release the medication over a projected six-month period, ensuring prolonged pain relief for patients suffering from moderate to severe osteoarthritis.
Precision Manufacturing for Reliable Results
In 2023, Calosyn completed preliminary manufacturing phases with Lonza, ensuring that our drug delivery system is not only innovative but also reliable. Through rigorous testing we identified the most viable formulation that meets our high standards. Our sustained-release method ensures that patients receive a steady, therapeutic dose over time, reducing the need for frequent injections and minimizing side effects associated with other osteoarthritis treatments.
Why Sustained-Release Matters
Traditional osteoarthritis treatments often require frequent dosing, leading to fluctuating drug levels and inconsistent pain relief. Calosyn’s sustained-release technology changes this by providing a steady, controlled release of verapamil directly to the affected area, mimicking the natural environment of the joint. This approach not only extends the effectiveness of the treatment but also contributes to a better quality of life for patients by reducing the frequency of treatments.
LOOKING AHEAD…
As we continue to refine our drug delivery system, Calosyn is committed to pushing the boundaries of what's possible in osteoarthritis treatment. We are confident our approach will set a new standard in sustained-release therapies for osteoarthritis and beyond.